Your new post is loading...
Your new post is loading...
BigField GEG Tech's insight:
Bluebird bio said today it has acquired a manufacturing facility in Durham, NC, from an undisclosed seller for $11.5 million, with the goal of producing lentiviral vectors for the company’s cell and gene therapies. No comment yet.
Sign up to comment
BigField GEG Tech's insight:
Researchers report promising results in a Phase 1 trial testing a new cell therapy using chimeric antigen receptor (CAR) T-cell technology on patients suffering from a treatment-resistant form of leukemia. The study, which successfully treated even cancers that had resisted a previous CAR T immunotherapy, was published in Nature Medicine
BigField GEG Tech's insight:
Junctional epidermolysis bullosa (JEB) is a severe and often lethal genetic disease caused by mutations in genes encoding the basement membrane component laminin-332. Surviving patients with JEB develop chronic wounds to the skin and mucosa, which impair their quality of life and lead to skin cancer. Here the authors show that autologous transgenic keratinocyte cultures regenerated an entire, fully functional epidermis on a seven-year-old child suffering from a devastating, life-threatening form of JEB. The proviral integration pattern was maintained in vivo and epidermal renewal did not cause any clonal selection. Clonal tracing showed that the human epidermis is sustained not by equipotent progenitors, but by a limited number of long-lived stem cells, detected as holoclones, that can extensively self-renew in vitro and in vivo and produce progenitors that replenish terminally differentiated keratinocytes. This study provides a blueprint that can be applied to other stem cell-mediated combined ex vivo cell and gene therapies.
BigField GEG Tech's insight:
The risk of tumor formation poses a challenge for human pluripotent stem cell (hPSC)‐based transplantation therapy. Specific and total elimination of tumorigenic hPSCs by suicide genes has not bee
OCT4 impedes cell fate redirection by the melanocyte lineage master regulator MITF in mouse ESCs
BigField GEG Tech's insight:
A new study published in Nature Communications reveals that it is possible to repurpose the function of different mature cells across the body — and harvest new tissue and organs from these cells. The research tracks the transformation of genetically manipulated cells into melanocytes, which are responsible for the production of skin pigment and essential to the body's auditory system.
BigField GEG Tech's insight:
In this work, the scientists have designed different WAS gene-specific CRISPR/Cas9 systems and compared their efficiency and specificity using K562 cells as a cellular model and plasmid nucleofection or integrative-deficient Lentiviral Vectors (IDLVs) for delivery. The different CRISPR/Cas9 and ZFNs SNs showed similar efficiency using plasmid nucleofection for delivery. However, dual IDLVs expressing ZFNs were more efficient than dual IDLVs expressing Cas9 and gRNA or that all-in-one IDLVs, expressing Cas9 and gRNA in the same vector. They also showed a similar behavior of heterodimeric ZFNs and CRISPR/Cas9 for Homology-Directed (HD) gene knock-in strategies, with 88% and 83% of the donors inserted in the WAS locus respectively while using homodimeric ZFNs only 45% of the insertions were on target. In summary, their data indicates that CRISPR/Cas9 and heterodimeric ZFNs are both good alternatives to further develop SNs-based gene therapy strategies for WAS. However IDLVs delivery of WAS-specific heterodimeric ZFNs was the best option of all systems compared in this study.
BigField GEG Tech's insight:
In this work, the scientist pseudotyped lentiviral vector (LV) vaccines with a modified Sindbis Virus glycoprotein so that they could deliver genes encoding the breast cancer antigen alpha-lactalbumin or erb-b2 receptor tyrosine kinase 2 directly to resident dendritic cells. Their results show that a single injection with targeted lentiviral vectors can be an effective immunotherapy for breast cancer. Furthermore, they could be combined with other immunotherapeutic regimens to improve outcomes for patients with breast cancer.
BigField GEG Tech's insight:
Neurophysiological phenomena that underlie the symptoms of autism remain unclear. Genetics-based mouse models of autism have suggested that there is an increase in the neuronal excitation/inhibition (E:I) balance. An optogenetically driven increase in this E:I balance leads to social deficits in mice. Using mice lacking CNTNAP2 , a gene known to be associated with autism in humans, Selimbeyoglu and colleagues now show that real-time optogenetic modulation of the E:I balance rescued social behavior deficits and hyperactivity in these animals. This study highlights the potential for modulating neural circuits in the brain as a strategy for treating autism.
BigField GEG Tech's insight:
Here the scientists show that independently of the starting material, operator, or device, the process consistently yielded a therapeutic dose of highly viable CAR T cells. Interestingly, the formulated product obtained with PM was comparable to that of HD with respect to cell composition, phenotype and function, even though the starting material differed significantly. Potent anti-tumor reactivity of the produced anti-CD20 CAR T cells was shown in vitro as well as in vivo. In summary, they demonstrated that the automated T cell transduction process meets the requirements for clinical manufacturing that we intend to use in two separate clinical trials for the treatment of melanoma and B cell lymphoma.
BigField GEG Tech's insight:
Gene and cell therapy research recently reached a fundamental milestone toward the goal to deliver new medicines for orphan diseases. In 2016, the European Commission granted market approval to GlaxoSmithKline (GSK) for ex vivo hematopoietic stem cell (HSC) gene therapy for the treatment of adenosine deaminase (ADA)‐deficient severe combined immunodeficiency (SCID), a very rare congenital disorder of the immune system. The new medicine, named Strimvelis™, is an advanced therapy medicinal product (ATMP) (Salmikangas et al , [2015][1]) originally developed by the San Raffaele Telethon Institute for Gene Therapy (SR‐Tiget), a joint venture between Telethon Foundation and San Raffaele Scientific Institute. This ATMP is the first ex vivo stem cell gene therapy to receive regulatory approval anywhere in the world. Strimvelis™ consists of a single infusion of autologous gene‐corrected HSC and is prepared from the patient's own bone marrow (BM) HSCs, which are genetically modified using a gamma‐retroviral vector to insert a functional copy of the ADA gene.
BigField GEG Tech's insight:
Lentiviral vectors have become a popular tool for gene transfer experiments and gene therapy approaches, particularly when stable gene transfer is required. They allow durable transgene expression because the vector integrates into the host cell genome. However, depending on the specific application, difficulties have persisted with respect to the efficiency and safety of this vector system. The article by Vink et al.1 in this issue of Molecular Therapy describes a new lentiviral vector termed LTR1 that is both more efficient and safer than currently employed versions.
The application of luciferase reporter genesReportergenes to provide quantitative outputs for the activation of promoters is a well-established technique in molecular biology. Luciferase catalyzes an
BigField GEG Tech's insight:
In this study, the scientits developed a high-throughput cloning strategy to develop lentiviral luciferase reporters driven by transcription factor activated synthetic promoters. Lentiviruses integrate their payload cassette into the host cell genome, thereby facilitating the study of gene expression not only in the transduced cells but also within all subsequent daughter cells. In this manuscript the authors describe the design, vector construction, lentiviral transduction, and luciferase quantitation of transcription factor activated reporters (TFARs) in vitro and in vivo.
BigField GEG Tech's insight:
In this study, the scientists evaluated the ocular and systemic tolerances of this lentiviral-based therapy (LV-RPE65) on healthy nonhuman primates (NHPs), without adjuvant systemic anti-inflammatory prophylaxis. |
BigField GEG Tech's insight:
In vivo delivery of a Cas9-based epigenetic gene activation system ameliorates disease phenotypes in mouse models of type I diabetes, acute kidney injury, and muscular dystrophy
BigField GEG Tech's insight:
In this study the scientists review the most commonly used indel detection methods and using a robust, sensitive, and cost efficient Indel Detection by Amplicon Analysis method, they have investigated the impact of the most commonly used CRISPR/Cas9 delivery formats, including lentivirus transduction, plasmid lipofection, and ribo nuclear protein electroporation, on the dynamics of indel profile formation. They observe rapid indel formation using RNP electroporation, especially with synthetic stabilized gRNA, as well as long-term decline in overall indel frequency with lipofectamine-based, plasmid transfection methods. Most methods reach peak editing on day 2–3 postdelivery. Furthermore, they find relative increase in frequency of larger size indels (>6 bp) under condition of persistent editing using stably integrated lentiviral gRNA and Cas9 vectors.
BigField GEG Tech's insight:
Horama has raised a second fundraising round that will support its lead candidate, a gene therapy for retinitis pigmentosa, through clinical trials.
HORA-PDE6B is intended to cure retinitis pigmentosa in patients that develop the disease because of a mutation in the PDE6β gene, which amounts to around 5,000 people in the US and Europe. The gene therapy consists of a recombinant adeno-associated virus (AAV) in which the viral DNA is replaced by a functional copy of the PDE6β gene.
BigField GEG Tech's insight:
Although gene therapy has been proposed for a variety of genetic disorders, including severe combined immunodeficiency, it has not yet found routine use in the clinic, in part because of potential complications. To help pave the way for safer translation of such gene therapy, Schiroli et al. studied potential approaches to it in mouse models of severe combined immunodeficiency. The authors systematically analyzed the outcomes of using different approaches to conditioning, different numbers of gene-edited cells, different techniques for editing the faulty gene, and other aspects of the technology to find the safest and most effective method.
BigField GEG Tech's insight:
The safety of lentiviral vectors is a factor in their acceptance as clinical therapies. In this issue of Molecular Therapy, Cornetta et al. (2017) screened 460 cell products for replication-competent lentivirus (RCL); none were positive. The low risk of RCL suggests that revisions to U.S. FDA testing guidelines are warranted.
BigField GEG Tech's insight:
Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.
BigField GEG Tech's insight:
Gene delivery vectors that do not rely on host cell genome integration offer several advantages for gene transfer, chiefly the avoidance of insertional mutagenesis and position effect variegation. However, unless engineered for replication and segregation, nonintegrating vectorswill dilute progressively in proliferating cells, and are not exempt of epigenetic effects. This article provides an overview of the main nonintegrating viral (adenoviral, adeno-associated viral, integration-deficient retro-lentiviral, poxviral), and nonviral (plasmid vectors, artificial chromosomes) vectors used for preclinical and clinical cell and gene therapy applications. Particular emphasis is placed on their use in hematologic disease.
BigField GEG Tech's insight:
As we anticipate the first-ever CAR-T therapy market approval we look at the important aspect of treatment delivery and viral vector strategies.
GEG Tech is a key player in the design and production of gene tranfer tools to generate CAR T & NK cells
https://www.geg-tech.com/services/advanced-service/car-t-cells
Lentiviral vectors are virus particles that can be used as a vaccine to stimulate the immune system to fight against specific pathogens. The vectors are derived from HIV, rendered non-pathogenic, and then engineered to carr
BigField GEG Tech's insight:
Lentiviral vectors are virus particles that can be used as a vaccine to stimulate the immune system to fight against specific pathogens. The vectors are derived from HIV, rendered non-pathogenic, and then engineered to carry genetic material into the body's immune cells; the genes program the cells to fight specific pathogens. New research from the laboratory of David Baltimore, president emeritus and the Robert Andrews Millikan Professor of Biology, shows that additional materials acquired during the vector's formation—namely, proteins and human genomic DNA—play an important role in activating the immune system. Understanding how lentiviral vectors interact with the immune system is critical to improving vaccines so as to maximize the immune response, and to understanding infectious processes occurring in natural pathogens.
Gene expression is controlled in activated neurons in the mouse brain using a two-component optogenetic system.
BigField GEG Tech's insight:
Here, the scientists present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner. In cultured neurons and brain slices, they show that Cal-Light drives expression of the reporter EGFP with high spatiotemporal resolution only in the presence of both blue light and calcium. Delivery of the Cal-Light components to the motor cortex of mice by viral vectors labels a subset of excitatory and inhibitory neurons related to learned lever-pressing behavior. By using Cal-Light to drive expression of the inhibitory receptor halorhodopsin (eNpHR), which responds to yellow light, we temporarily inhibit the lever-pressing behavior, confirming that the labeled neurons mediate the behavior. Thus, Cal-Light enables dissection of neural circuits underlying complex mammalian behaviors with high spatiotemporal precision.
BigField GEG Tech's insight:
Here the scientists demonstrated marked though distinct anti-silencing activity in the pluripotent state and during PSC-differentiation for several of the CBX3 subfragments. This activity was significantly correlated with CpG content as well as endogenous transcriptional activity. Interestingly, also a scrambled CBX3 version with preserved CpG-sites retained the anti-silencing activity despite the lack of endogenous promoter activity. These data therefore highlight the importance of CpG-sites and transcriptional activity for UCOE functionality and suggest contributions from different mechanisms to the overall anti-silencing function of the CBX3 element.
BigField GEG Tech's insight:
Here the scientists packaged SaCas9/gRNA constructs into an AAV vector and systemically delivered them to mdx/Utr+/- neonates. They showed that CRIPSR-mediated genome editing efficiently excised the mutant exon 23 in dystrophic mice and immunofluorescence data supported the restoration of dystrophin protein expression in dystrophic cardiac muscles to a level approaching 40%. Moreover, there was a noted restoration in the architecture of cardiac muscle fibers and a reduction in the extent of fibrosis in dystrophin deficient hearts. The contractility of cardiac papillary muscles was also restored in CRISPR-edited cardiac muscles compared to untreated controls. Furthermore, the targeted deep sequencing results confirmed that our AAV-CRISPR-Cas9 strategy was very efficient in deleting the ~23 kb of intervening genomic sequences. |
Your new post is loading...